Why is Teva Pharma stock surging today?

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

The Tel Aviv Stock Exchange rose after the Bank of Israel cut interest rates to 3.25%. The Tel Aviv 35 Index gained 0.22%, while Dimri led gains with a 5.47% rise. OPC Energy fell 4.67%, the biggest decline. Key movers included Elbit Systems, Teva, and Ormat, which rose, and Camtek and Tower Semiconductor, which fell.

President Trump expanded his Most-Favored-Nation drug pricing initiative to 26 companies, covering 89% of the branded drug market. New participants include Alcon, Astellas Pharma, and Teva, among others, agreeing to tie Medicaid drug prices to those in other developed countries. The deals also involve $19.6 billion in U.S. manufacturing investments. According to HHS Secretary Robert F. Kennedy Jr., the agreements cover nine out of 10 drugs used by Americans.

Nine mid-sized drug manufacturers, including Teva Pharmaceuticals and Sun Pharma, agreed to lower U.S. drug prices under 'most-favored-nation' deals, joining 17 others. The deals cover 89% of the U.S. branded drug market, aiming to save billions for Medicaid and ensure U.S. access to lower prices. Companies committed $19.6B to U.S. manufacturing and donated key pharmaceutical ingredients to a national reserve.

Nine mid-sized pharma companies, including Teva, signed MFN pricing deals with the White House, covering 89% of the US branded drug market. The policy ties US drug prices to the lowest prices charged abroad. The administration claims the deals will reduce prices for costly, chronic, and rare diseases and secure $20B in US manufacturing investments. Public Citizen criticizes the deals as ineffective.

President Trump announced drug pricing agreements with nine pharmaceutical companies, including Alcon (ALC), BeOne (ONC), BridgeBio (BBIO), and Teva (TEVA). The deals require discounts on outpatient drugs for Medicaid and $19.6B in U.S. manufacturing investments. This expands the total to 26 companies, covering 90% of the U.S. market. The White House estimates $529B in savings over a decade.